Showing results (121-130 of 158) with videos related to
Sort By:
Pageof 16
Presse Medicale (Paris, France : 1983)|January 18, 1992
[Treatment of venous thrombosis with low molecular weight heparin and fluindione]J N Fiessinger, J F Paul, M Alhenc-Gelas, et al.Journal of Protein Chemistry|February 26, 2000
Identification of protein C epitopes altered during its nanoencapsulationD Chognot, M F Zambaux, F Bonneaux, et al.British Journal of Haematology|August 1, 1987
An abnormal antithrombin III (AT III) with low heparin affinity: AT III ClichyM Aiach, D François, P Priollet, et al.Angiology|October 1, 1980
Local urokinase in arterial thromboembolismJ N Fiessinger, M Vayssairat, Y Juillet, et al.Annales De Medecine Interne|January 1, 1979
[Use of urokinase during surgery: a new approach to the treatment of vascular obliterative disease (author's transl)]J N Fiessinger, M Vayssairat, Y Juillet, et al.Annales De Medecine Interne|January 1, 1986
[Treatment with the urokinase-lysyl plasminogen combination of developmental outbreaks of arteriopathies]J F Vitoux, M Roncato, J M Pernes, et al.Thrombosis and Haemostasis|December 2, 1991
Antithrombin III: a database of mutationsD A Lane, H Ireland, R J Olds, et al.Thrombosis and Haemostasis|June 1, 1994
Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study GroupM Alhenc-Gelas, C Jestin-Le Guernic, J F Vitoux, et al.Dermatologica|January 1, 1986
Von Recklinghausen neurofibromatosis and hereditary plasminogen deficiencyP Priollet, M Roncato, M Vayssairat, et al.The Journal of Clinical Investigation|October 1, 1989
Molecular characterization of antithrombin III (ATIII) variants using polymerase chain reaction. Identification of the ATIII Charleville as an Ala 384 Pro mutationP Molho-Sabatier, M Aiach, I Gaillard, et al.Pageof 16